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A B S T R A C T   
Renal ischemia reperfusion (IR) injury leads to significant patient morbidity and mortality, and its amelioration 
is an urgent unmet clinical need. Succinate accumulates during ischemia and its oxidation by the mitochondrial 
enzyme succinate dehydrogenase (SDH) drives the ROS production that underlies IR injury. Consequently, 
compounds that inhibit SDH may have therapeutic potential against renal IR injury. Among these, the 
competitive SDH inhibitor malonate, administered as a cell-permeable malonate ester prodrug, has shown 
promise in models of cardiac IR injury, but the efficacy of malonate ester prodrugs against renal IR injury have 
not been investigated. Here we show that succinate accumulates during ischemia in mouse, pig and human 
models of renal IR injury, and that its rapid oxidation by SDH upon reperfusion drives IR injury. We then show 
that the malonate ester prodrug, dimethyl malonate (DMM), can ameliorate renal IR injury when administered at 
reperfusion but not prior to ischemia in the mouse. Finally, we show that another malonate ester prodrug, 
diacetoxymethyl malonate (MAM), is more potent than DMM because of its faster esterase hydrolysis. Our data 
show that the mitochondrial mechanisms of renal IR injury are conserved in the mouse, pig and human and that 
inhibition of SDH by ‘tuned’ malonate ester prodrugs, such as MAM, is a promising therapeutic strategy in the 
treatment of clinical renal IR injury.   
1. Introduction 
Ischemia reperfusion (IR) injury occurs upon the return of an 
oxygenated blood supply to an organ or tissue following a period of 
ischemia [1,2]. Paradoxically, the return of oxygenated blood leads to 
an increase in the level of injury over and above that which occurs 
during ischemia alone [1,3]. This is due to the production of reactive 
oxygen species (ROS) during reperfusion, primarily from mitochondria, 
which go on to initiate much of the downstream damage leading to 
organ or tissue injury [4,5]. The kidney has the second highest 
mitochondrial content of any organ after the heart [6]. The majority of 
mitochondria are located within the proximal tubule cells of the kidney 
where they provide energy for the reabsorption of nutrients and ions 
from the filtrate and are the renal cell type most susceptible to IR injury 
[7]. The kidney undergoes IR injury in a number of clinical contexts 
including hypovolaemic shock [8], cardiothoracic surgery [9], trans-
plantation [10] and the resection of renal tumours [11], which is asso-
ciated with significant morbidity and mortality [12]. A number of 
promising interventions targeting mitochondria have previously been 
identified in pre-clinical models of renal IR injury [13–15]. Even so, 
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none have so far been successfully translated to humans. This may partly 
reflect the greater complexity of injury in the clinical scenario, and 
amelioration of renal IR injury remains an urgent unmet need. 
While the production of ROS on reperfusion was traditionally 
thought to occur at random sites within mitochondria as a result of 
damage to the electron transport chain, a specific mechanism of mito-
chondrial ROS production during IR injury has recently been proposed 
[16,17]. Succinate accumulates during ischemia due to reduction of the 
coenzyme Q (CoQ) pool that blocks succinate oxidation and which can 
also cause the reduction of fumarate to succinate by reversal of succinate 
dehydrogenase (SDH). Upon reperfusion the accumulated succinate is 
rapidly oxidised, driving ROS production by reverse electron transport 
(RET) at Complex I. The ROS production associated with RET at Com-
plex I is driven by the near maximal proton motive force which develops 
upon reperfusion, due to the degradation of adenine nucleotides during 
ischemia that deprives the FOF1-ATP synthase of its substrate, in 
conjunction with a reduced CoQ pool. The superoxide produced by 
Complex I upon reperfusion is converted to hydrogen peroxide by 
manganese superoxide dismutase (MnSOD) and goes on to initiate much 
of the downstream damage leading to IR injury [2,18]. The accumula-
tion of succinate during ischemia and its subsequent oxidation upon 
reperfusion has previously been demonstrated in the mouse kidney [19], 
however uncertainty remains as to whether the same mechanism occurs 
in human kidneys [20] and whether targeting SDH upon reperfusion has 
therapeutic potential. 
Malonate is a competitive inhibitor of SDH that can inhibit succinate 
accumulation during ischemia and its oxidation upon reperfusion, 
thereby reducing mitochondrial ROS production and IR injury (Fig. 1). 
However, malonate is a charged molecule and must be given as a cell- 
permeable prodrug to enter tissues in vivo. This can be achieved by 
administering malonate as an ester prodrug where the charged carbox-
ylate groups are masked by short-chain alcohols, enabling the prodrug 
to passively diffuse through lipid membranes [21]. Once inside, intra-
cellular carboxylesterases, such as CES1 and CES2, can hydrolyse the 
ester bonds of the prodrug, releasing the active drug malonate (Fig. 2a). 
Malonate ester prodrugs that are slowly hydrolysed by carboxylesterases 
may only be suited to inhibiting succinate accumulation during 
ischemia, while malonate ester prodrugs hydrolysed more rapidly may 
be suitable for the inhibition of succinate oxidation upon reperfusion as 
well [22]. Acyloxymethyl esters of carboxylic acids, carbamic acids and 
phosphonic and phosphoric acids are widely used as prodrugs because 
the acyl group is easily hydrolysed by carboxylesterases and tuneable 
[21]. This makes them particularly attractive as ester prodrugs of mal-
onate (Fig. 2a). 
Here, we first investigate the metabolic changes that occur during 
ischemia in mouse, pig and human kidneys to determine whether the 
mechanism of renal IR injury previously described in the mouse is 
conserved across species. We then investigate the efficacy of two mal-
onate ester prodrugs, dimethyl malonate (DMM) and diacetoxymethyl 
malonate (MAM, an acyloxymethyl diester) (Fig. 2b), in targeting suc-
cinate metabolism during renal IR injury in the mouse. Acetoxymethyl 
groups are known to be rapidly hydrolysed by esterases and thus may 
result in more rapid production of therapeutic levels of malonate upon 
reperfusion [23]. We show that administration of DMM reduces mouse 
renal IR injury, but that diacetoxymethyl malonate, a more rapidly 
hydrolysed malonate prodrug, is far more potent at preventing kidney IR 
injury. 
2. Materials and methods 
2.1. Synthesis of diacetoxymethyl malonate 
Diacetoxymethyl malonate (MAM) was prepared by O-alkylation of 
malonate with acetoxymethyl bromide following the procedure of Bao 
et al. [24]. 
2.2. Model of renal IR injury in the mouse 
Female C57BL/6J mice, aged 10–16 weeks and weighing ~20g 
(Charles River Laboratories, UK) were maintained in specific pathogen- 
free facilities with ad libitum food and water. All procedures were 
approved by the UK Home Office under the Animals (Scientific Pro-
cedures) Act 1986. Mice were anaesthetised with 1.5–2% isoflurane and 
2.0 L/min oxygen and their core temperature maintained at 36.0 � 0.5 
�C throughout the procedure using a homeothermic heat mat (Harvard 
Apparatus, UK). A midline laparotomy was performed and the renal hila 
were dissected. To induce ischemia, a Micro-Serrofine clamp (15 mm, 
Fine Science Tools, Germany) was placed over the renal hilum of each 
Fig. 1. Inhibition of Succinate Dehydrogenase 
During Ischemia Reperfusion Injury with Malo-
nate. (a) During ischemia, succinate accumulates due 
to reversal of succinate dehydrogenase (SDH). The 
accumulated succinate acts as a store of electrons 
capable of driving reverse electron transport (RET) 
and reactive oxygen species (ROS) production when 
rapidly re-oxidised on reperfusion. SDH reversal and 
succinate accumulation may be inhibited during 
ischemia by the competitive inhibitor of SDH, malo-
nate. (b) On reperfusion, accumulated succinate is 
rapidly re-oxidised by SDH leading to reverse electron 
transport (RET) and the production of superoxide (O2_) 
from the flavin mononucleotide site of Complex I (CI). 
Rapid re-oxidation of succinate by SDH on reperfusion 
may also be inhibited by the competitive inhibitor of 
SDH, malonate, which prevents RET and ROS pro-
duction. Intermembrane space (IMS). Inner mito-
chondrial membrane (IMM).   
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kidney to occlude the renal artery and vein. During ischemia, the 
midline laparotomy was closed using 5-0 absorbable suture (Safil®, 
Braun, Germany) to maintain core body temperature and minimise 
losses from evaporation. Successful occlusion of the renal vessels was 
confirmed by the development of a purplish colour to each kidney. For 
reperfusion experiments, Micro-Serrefine clamps were removed from 
the renal hila following ischemia and return of the kidney(s) to normal 
colour was noted. 
In non-terminal procedures, the abdominal wall was closed in two 
layers with 5-0 absorbable suture (Safil®, Braun, Germany) and mice 
were re-hydrated with 500 μL saline injected subcutaneously. Mice were 
then recovered in an incubator set at 28 �C on soft, dry bedding with 
access to food and water. A subcutaneous injection buprenorphine (0.1 
mg/kg) was given for pain relief in recovery experiments. 
2.3. Infusions 
In all experiments, compounds were administered as an infusion in a 
total volume of 160 μL saline. A syringe driver (Model 11 Syringe Pump, 
Harvard Apparatus) was used to deliver compounds at a rate of 16 μL/ 
min through an infusion line (Portex Polyethylene Tubing, Smiths 
Medical International, UK) inserted directly into the inferior vena cava 
(IVC) with a 30 G needle. In experiments aimed at inhibiting succinate 
accumulation, saline or DMM (40, 80, 160, 320 and 640 mg/kg) were 
administered as an infusion beginning 10 min prior to the onset of 
ischemia. In experiments aimed at inhibiting succinate oxidation on 
reperfusion, saline, DMM (160 mg/kg), 1% v/v dimethyl sulfoxide 
(DMSO) or MAM (16 mg/kg) in 1% v/v DMSO were administered as a 
10 min infusion beginning 5 min prior to the onset of reperfusion. 
2.4. Administration of MitoB 
MitoB and internal standards were synthesised as previously 
described [25]. MitoB (20 nmol in 50 μL saline þ 5% (v/v) DMSO) was 
given as an intravenous injection directly into the IVC 30 min prior to 
the onset of ischemia. 
2.5. Tissue collection and storage 
Tissue and whole blood were collected from mice under terminal 
anaesthesia. Approximately 500 μL whole blood was collected directly 
from the IVC using a 1 mL syringe and 27 G needle. Whole blood was 
transferred to 250 μL capillary action collection tubes and allowed to 
clot. Tubes were then centrifuged at 3000 g for 10 min to separate the 
clot from the serum. The serum was then collected and stored at   70 �C 
until further processing and analysis. Kidneys for metabolomic analysis 
were rapidly excised from the mouse and frozen in liquid nitrogen (LN2) 
using Wollenburger clamps. Frozen tissue was then stored at   70 �C 
until further processing. Rapid removal and freezing of tissue in Wol-
lenberger clamps was essential in preserving the metabolic profile of the 
kidney at each stage of the experiment [26]. 
2.6. Pig model of renal ischemia 
Large male and female Landrace pigs weighing 40–70 kg were sup-
plied by Convance, Huntington, UK. All procedures approved by the UK 
Home Office under the Animals (Scientific Procedures) Act 1986. Pigs 
were medicated with intramuscular ketamine (10 mg/kg), medetomi-
dine (0.02 mg/kg) and midazolam (0.1 mg/kg). A peripheral intrave-
nous catheter was placed in the marginal ear vein and anaesthesia was 
induced with propofol to effect. Pigs were intubated and 100% oxygen 
supplied with intermittent positive pressure ventilation was used to 
maintain normocapnia. Anaesthesia was maintained with continuous 
infusions of propofol (starting at 10 mg/kg/hr and titrating down to 
effect) and either remifentanil (starting at 2.4 mg/kg/h and titrating up 
to effect) or alfentanil (starting at 30 μg/kg/h and titrating up to effect). 
If required, isoflurane was provided at approximately 2% to maintain 
anaesthesia. Saline was administered intravenously at approximately 
10 mL/kg/h. During anaesthesia a Datex Ohmeda Cardiocap monitoring 
system was used to monitor ECG waveform, pulse oximetry, tempera-
ture and capnography parameters. 
A midline laparotomy was performed and the bowel mobilised to 
expose the renal hila. The renal hila were dissected and renal artery and 
vein slung using a 3-0 vicryl tie (Ethicon, Johnson & Johnson, UK) on 
both sides. The ureters were identified and each kidney was freed from 
the underlying connective tissue. Heparin (500 IU/kg, CP Pharmaceu-
ticals, UK) was then administered via the marginal ear vein. Five mi-
nutes after the administration of heparin, a wedge tissue biopsy was 
taken from the kidney and rapidly clamp frozen in LN2 using Wollen-
burger clamps. The renal artery and vein of each kidney were then tied 
and the renal vessels and ureter divided. Kidneys were then maintained 
at the physiological temperature of 38 �C in the abdomen of the pig for 
30 min [27]. At the end of 30 min ischemia, a second wedge biopsy was 
taken from each kidney and rapidly clamp frozen in LN2 using 
Fig. 2. Malonate Ester Prodrugs Used to Target Succinate Dehydrogenase In Vivo. (a) Malonate ester prodrugs and particularly acyloxymethyl ester prodrugs 
are hydrolysed by intracellular carboxylesterases (CES1 and CES2) to release malonate. (b) Chemical structure of succinate, malonate, dimethyl malonate (DMM) and 
diacetoxymethyl malonate (MAM). 
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Wollenburger clamps. Frozen tissue was then stored at   70 �C until 
further processing. 
2.7. Acceptance of declined human kidneys for research 
Human kidneys declined for organ transplantation were accepted for 
research according to NHS Blood and Transplant guidelines. Full ethical 
approval for the use of human kidneys for the investigation of ischemia 
reperfusion injury had been awarded in advance (NREC 15/NE/0408) 
and informed consent from the families of organ donors was obtained. 
Declined human kidneys were delivered to our laboratory under con-
ditions of static cold storage. Deceased donor demographics of declined 
human kidneys accepted for research are shown in Table 1. 
2.8. Ex vivo normothermic perfusion of human kidneys 
Ex vivo normothermic perfusion of human kidneys was conducted as 
previously described by Nicholson et al. [28]. In brief, declined human 
kidneys were reperfused for 1 h on a modified paediatric cardiopul-
monary bypass circuit (Medtronic, UK) using a warmed (37.0 � 1.0 �C), 
oxygenated, ABO-matched, whole-blood perfusate (300 mL whole 
blood, 300 mL Ringers solution (Baxter Healthcare, US), 2.5 g mannitol, 
0.06 g creatinine, 10 mL 8.4% sodium bicarbonate, 500 IU heparin) at a 
constant pump-speed of 1500 rpm. During EVNP, Ringer’s solution was 
used to replace the volume of perfusate lost in the urine (titrated to the 
rate of urine production) and the perfusate was supplemented with a 5% 
glucose solution (Baxter Healthcare, US) at a rate of 5 mL/h and an 
amino acid solution (Synthamin 17 10.0%, Baxter Healthcare, US) with 
added insulin (0.2 IU/mL) and 8.4% sodium bicarbonate (0.3 mL per mL 
Synthamin) at a rate of 20 mL/h. 
Following 1 h EVNP, a tissue wedge biopsy was taken from cortex of 
the kidney and rapidly clamp frozen in LN2 using Wollenburger clamps. 
Declined human kidneys were then removed from the circuit, placed in a 
plastic bag and submerged in a water bath set to 36 �C to simulate renal 
warm ischemia. Following 30 min ischemia a second wedge biopsy was 
taken from the cortex of the kidney and rapidly clamp frozen in LN2 
using Wollenburger clamps. Frozen tissue was then stored at   70 �C 
until further processing. 
2.9. Extraction of polar metabolites for liquid chromotography tandem 
mass spectrometry (LC-MS/MS) 
For each sample, approximately 20 mg of clamp frozen tissue was 
weighed out on dry ice into a pre-cooled Precellys tube (Hard tissue 
homogenising CK28-R - 2 mL; Bertin Instruments, France). After 
weighing, 25 μL/mg of pre-cooled extraction buffer (50% (v/v) mass 
spectrometry (MS)-grade methanol (Thermo Fisher Scientific, UK), 30% 
(v/v) MS-grade acetonitrile (Romil, UK), 20% MS-grade water (Thermo 
Fisher Scientific, UK) and 100 ng/mL HEPES free acid) was added to 
each sample along with 20 μL internal standard containing 1 nmol 13C4- 
succinate and 1 nmol 13C3-malonate. Samples were homogenised using a 
Precellys 24 tissue homogeniser (6500 rpm, 2 � 15 s, Bertin Instruments, 
France) and transferred back onto dry ice. Following homogenisation, 
samples were centrifuged (17,000 g, 10 min, 4 �C) and the supernatant 
transferred to a pre-cooled microcentrifuge tube on wet ice. Samples 
were centrifuged again (17,000 g, 10 min, 4 �C) and the supernatant 
transferred to a pre-cooled MS vial. Vials were stored at   70 �C until 
analysis. 
2.10. Extraction of MitoP and MitoB for LC-MS/MS 
For each sample, approximately 50 mg of clamp frozen tissue was 
weighed out on dry ice into a 2 mL microcentrifuge tube. One spatula of 
zirconium oxide beads (Next Advance, USA), approximately the size of 
the tissue, was added to each sample along with 200 μL MitoP/B 
extraction buffer A (60% (v/v) MS-grade acetonitrile (Romil, UK), 0.1% 
MS-grade formic acid (Merck, UK), 39.9% MS-grade water (Thermo 
Fisher Scientific, UK)) and 10 μL internal standard containing 100 pmol 
d15-MitoB and 50 pmol d15-MitoP. Samples were then homogenised 
using a Bullet Blender (speed 8, 4 min, Next Advance, USA) and left for 
30 min at 4 �C. Samples were then centrifuged (17,000 g, 10 min) and 
the supernatant transferred to a 96 well filter plate. The sample pellet 
was then resuspended in 200 μL MitoP/B extraction buffer A, vortexed 
for approximately 30 s and centrifuged again (17,000 g, 10 min). The 
second supernatant was then added to first supernatant in the corre-
sponding well of the filter plate and samples were vacuum filtered into 
the collection plate. The filtered supernatant of each sample was then 
transferred to a fresh 2 mL microcentrifuge tubes and dried in a speed 
vac overnight (40 �C). Dried samples were then resuspended in 250 μL 
MitoP/B extraction buffer B (20% (v/v) MS-grade acetonitrile (Romil, 
UK), 0.1% MS-grade formic acid (Merck, UK), 79.9% MS-grade water 
(Thermo Fisher Scientific, UK)), vortexed for 5 min and centrifuged 
(17,000 g, 10 min). The supernatant was then transferred to MS vials 
and stored at   70 �C until analysis. 
2.11. LC-MS/MS of succinate and malonate 
Samples were analysed using an LCMS-8060 mass spectrometer 
(Shimadzu, UK) with a Nexera X2 UHPLC system (Shimadzu, UK). 
Sample separation was achieved using a SeQuant®ZIC®-HILIC column 
(3.5 μg, 100 Å, 150 � 2.1 mm, 30 �C column temperature; MerckMil-
lipore, UK) with a ZIC®-HILIC guard column (200 Å, 1 � 5 mm). A flow 
rate of 200 μl/min was used with mobile phases of 10 mM ammonium 
bicarbonate (pH unchanged) and B) 100% acetonitrile. The mass spec-
trometer was operated in negative ion mode with multiple reaction 
monitoring (MRM). Sample spectra were acquired using Labsolutions 
software (Shimadzu, UK) and the peak area for each compound of in-
terest measured relative to the internal standard. Sample concentrations 
were then calculated from a standard curve of known compound con-
centrations produced by LC-MS/MS in a similar manner. 
2.12. LC-MS/MS of MitoP and MitoB 
A Waters Xevo TQ-S triple-quadrupole mass spectrometer was used 
for MS analysis. Electrospray ionization was in positive ion mode; pa-
rameters were as follows: capillary voltage, 3.2 kV; cone voltage, 79 V; 
ion source temperature, 150 �C; collision energy, 45 V. Nitrogen and 
argon were used as the curtain and the collision gases, respectively. LC- 
MS/MS analyses were carried out using a front end I-class Aquity LC 
system (Waters). Samples were cooled and 2 mL injected using a 15 mL 
flow-through needle and RP-HPLC was carried out at 30 �C using an 
Acquity UPLC BEH C18 1.μm, 1 3 50 mm column (Waters). Buffers were 
5% (v/v) ACN/0.1% (v/v) formic acid (FA) in water (MS buffer A) and 
90% (v/v) ACN/0.1% (v/v) FA (MS buffer B). A gradient was run at 200 
mL/min: 0–0.3 min, 5% B; 0.3–3 min, 5–100% B; 4–4.1 min, 100–5% B; 
4.1–4.6 min, 5% B. Eluent was diverted to waste at 0–1 and 4-4.6 min 
acquisition time using an in-line divert valve. Multiple reaction moni-
toring in positive ion mode was used for compound detection. 
Table 1 
Deceased donor demographics of declined human kidneys used to investigate 
the metabolic changes in the kidney under conditions of warm ischemia.  
Variables Donor 1 Donor 2 Donor 3 Donor 4 
Donor age (y) 55 65 64 69 











Static cold storage 
time (h) 
17 6 13 12  
a Donation after circulatory death. 
b Donation after brainstem death. 
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2.13. ATP/ADP luciferase assay 
ATP and ADP concentrations were measured using a Luciferase 
based assay as described by Strehler et al. [29] and performed by Martin 
et al. [30]. In brief, approximately 10 mg of clamp frozen tissue was 
weighed out on dry ice into pre-cooled Precellys tubes (Hard tissue 
homogenising CK28-R - 2 mL; Bertin Instruments, France). After 
weighing, 100 μL/mg of ice-cold perchloric acid extractant (3% (v/v) 
HClO4, 2 mM Na2-EDTA, 0.5% Triton X-100) was added to each sample. 
Samples were then homogenised using a Precellys 24 tissue homoge-
niser (6500 rpm, 2 � 15 s, Bertin Instruments, France) transferring 
samples back onto wet ice between cycles. Following homogenisation, 
samples were centrifuged (10,000g, 1 min, 4 �C) and the supernatant 
diluted in ice cold perchloric acid extractant to a concentration of 1 mg 
frozen tissue per mL. Samples along with ATP and ADP standards were 
neutralised to pH 7 using potassium hydroxide solution (2 M KOH, 2 mM 
Na2-EDTA, 50 mM MOPS). To measure ADP concentration, 250 μl of 
neutralised sample was added to 250 μL ATP sulfurylase assay buffer 
(20 mM Na2MoO4, 5 mM GMP, 0.2 U ATP sulfurylase (New England 
Biolabs, USA), in Tris-HCl buffer (100 mM Tris-HCl, 10 mM MgCl2 (pH 
8.0)) and incubated for 30 min at 30 �C to convert the sample’s ATP to 
AMP. ADP samples were then heated at 100 �C for 5 min and then cooled 
on ice. Standards (100 μL), samples for ATP measurement (100 μL) or 
samples for ADP measurement (200 μL) (in duplicate) were then added 
to 400 μL Tris-acetate (TA) buffer (100 mM Tris, 2 mM Na2-EDTA, 50 
mM MgCl2, pH 7.75 with glacial acetic acid) in luminometer tubes. To 
measure ADP concentration, 10 μL pyruvate kinase solution (100 mM 
PEP, 6 U pyruvate kinase suspension (Sigma #P1506)) was added to one 
set of samples for ADP measurement and incubated for 30 min at 25 �C 
in the dark to convert ADP to ATP. The other duplicate tube (without 
addition of pyruvate kinase solution) served as an ADP ‘blank’ value. 
The samples were then all assayed for ATP content in a Berthold Auto-
Lumat Plus luminometer by addition of (100 μL) Luciferase/Luciferin 
Solution (7.5 mM DTT, 0.4 mg/mLBSA, (1.92 μg) luciferase/mL (SIGMA 
#L9506), 120 μM D-luciferin (SIGMA #L9504), made in TA buffer (25% 
(v/v) glycerol)), delivered via auto injection, protected from light. 
Bioluminescence of the ATP- dependent luciferase activity was 
measured for 45 s post injection and the data quantified against standard 
curves. 
2.14. Measurement of serum creatinine 
Serum creatinine was measured on an automated biochemical ana-
lyser (Siemens Dimension RxL analyser, Siemens AG, Healthcare Divi-
sion, Germany) by the Jaffe reaction. This assay was performed by 
Cambridge Biochemical Analysis Laboratory, Addenbrooke’s Hospital, 
Cambridge, UK. 
2.15. Statistical analysis 
Mice were picked at random from the same cage and assigned to 
control or experimental arms. Equal numbers of right and left kidneys 
were allocated to each experimental group. MS and serum creatinine 
samples were analysed blinded to the experimental group identity. Data 
are presented as mean � SEM. Statistical analysis was performed using 
Prism 7.0 (Graphpad, USA). Comparisons between two datasets were 
assessed using an unpaired, two-tailed Student’s t-test assuming equal 
variance. We note that due to the number of data points it was not 
possible to confirm normality of distribution in all cases. Comparisons 
between multiple datasets were assessed using one or two-way analysis 
of variance (ANOVA) followed by Dunnett’s, Tukey’s or Sidak’s multiple 
comparisons test. P values < 0.05 were considered to be statistically 
significant. 
3. Results 
3.1. Ischemia time and injury severity following renal IR in the mouse 
In order to investigate the therapeutic effect of malonate ester pro-
drugs on renal IR injury we first established a mouse model. To do this 
we investigated varying periods of bilateral renal ischemia followed by 
reperfusion (of both kidneys) with the level of serum creatinine con-
centration at 24 h used to measure the extent of renal IR injury (Fig. 3a). 
Exposure to 15 min ischemia had no effect on serum creatinine (Fig. 3a), 
likely due to the large reserve capacity of the kidney, while mice exposed 
to more than 30 min ischemia did not survive reperfusion. Intermediate 
levels of ischemia (18–30 min) led to a significant increase in creatinine 
at 24 h with longer ischemia times leading to prolonged recovery of 
animals on reperfusion. 
3.2. Succinate metabolism during renal IR injury in the mouse 
We next investigated the metabolic changes in the rapidly frozen 
[26] mouse kidney at the end of various periods of ischemia and also 
following 10 min reperfusion after ischemia (Fig. 3b). Tissue succinate 
levels were increased ~10 fold compared to normoxic controls at all 
ischemic times and reached a maximum within 5 min of ischemia 
(Fig. 3c). After 10 min reperfusion following all periods of ischemia, the 
tissue succinate level returned to normoxic levels. Thus succinate is 
accumulated during ischemia and rapidly oxidised upon reperfusion in 
our model of kidney IR injury. 
3.3. Changes in ATP and ADP during renal IR injury in the mouse 
We next determined the ATP/ADP ratio and the total ATP and ADP 
concentration within the kidney during ischemia and upon reperfusion. 
The ATP/ADP ratio decreased within 5 min ischemia and remained low 
(Fig. 3d). The ATP/ADP ratio recovered fully after 10 min reperfusion 
following 5 min ischemia, but the recovery was less following longer 
periods of ischemia (Fig. 3d). 
The sum of the concentration of the adenine nucleotides, ATP and 
ADP, decreased at all times of ischemia (Fig. 3e). Upon 10 min reper-
fusion after various times of ischemia, the sum of the ATP and ADP 
concentrations recovered fully after 5 min ischemia, but remained 
significantly decreased following longer ischemia times. This suggests 
ATP could be rapidly regenerated from ADP upon reperfusion following 
5 min ischemia but not at longer ischemic times [19]. 
3.4. Mitochondrial ROS production during renal IR injury in the mouse 
To measure mitochondrial ROS production in the kidney upon 
reperfusion, mice were administered the ratiometric MS probe, MitoB 
[31] which reacts selectively with hydrogen peroxide within mito-
chondria to form MitoP. There was a significant increase in the 
MitoP/MitoB ratio upon reperfusion following 10 min ischemia (Fig. 3f) 
suggesting a burst of mitochondrial ROS production had occurred. 
3.5. Conservation of metabolic changes during ischemia in mouse, pig and 
human kidneys 
To determine whether our findings in the mouse were translatable, 
we next investigated the metabolic changes that occur in the pig and 
human kidney during ischemia. The kidneys were removed from anes-
thetised pigs and exposed to 30 min ischemia (Fig. 4a). Human kidneys 
retrieved for transplantation but subsequently offered for research were 
first reperfused for 60 min with oxygenated blood using an ex vivo 
normothermic perfusion (EVNP) system, then exposed to 30 min 
ischemia (Fig. 4b and c) [28,32]. During EVNP, declined human kidneys 
had an average (mean � SD, N ¼ 4) renal blood flow of 83 � 32 
mL/min/100g and a total urine output of 12 � 11 mL/h/100g. 
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In both pig and human kidneys 30 min ischemia led to a 5-fold in-
crease in succinate (Fig. 4d), a decrease in the ATP/ADP ratio (Fig. 4e) 
and a drop in the total ATP and ADP nucleotide concentrations (Fig. 4f) 
compared to normoxia. Of note, the absolute levels of succinate that 
accumulated after ischemia were similar across the three species 
(Fig. 4g). Together these findings suggest that ischemic succinate 
metabolism in the kidney is conserved in mice, pigs and humans. 
3.6. Administration of DMM prior to ischemia is not protective against 
renal IRI 
To determine whether malonate ester-prodrugs inhibit succinate 
accumulation during ischemia in the mouse kidney, DMM was given as 
an infusion to mice 10 min prior to the onset of ischemia (Fig. 5a). There 
was a dose-dependent increase in the malonate concentration in DMM- 
treated mice at the end of the infusion and after 20 min ischemia 
(Fig. 5b). However, there was no decrease in the succinate concentration 
by malonate at 20 min ischemia (Fig. 5c). There was also an increase in 
succinate at higher DMM concentrations prior to ischemia due to the 
Fig. 3. Metabolic Changes During Ischemia Reperfusion in the Mouse Kidney. (a) Serum creatinine concentration (n ¼ 3–4) at 24 h reperfusion following 
bilateral renal ischemia for the indicated durations. Control values represent serum creatinine concentration in age-matched mice that have not undergone bilateral 
renal IR injury. (b) Model used to investigate the metabolic changes during renal IR injury in the mouse. Mice underwent bilateral renal ischemia for the indicated 
durations, at the end of which one kidney was removed and rapidly clamp frozen in LN2 using Wollenburger clamps (End-Isc). The second kidney was reperfused for 
10 min and then removed and rapidly clamp frozen in LN2 using Wollenberger clamps also (Rep). (c) Tissue succinate concentration (n ¼ 4), (d) ATP/ADP ratio (n ¼
3–4) and (e) sum of the ATP and ADP concentrations (n ¼ 3–4) at the end of ischemia (End-Isc) and at 10 min reperfusion (Rep). Control kidneys (0 min) were 
removed from the mouse under conditions of normoxia. (f) Relative increase in MitoP/MitoB ratio on reperfusion (n ¼ 3–4) calculated from the MitoP/MitoB ratio in 
the kidney at 10 min reperfusion (Rep) over the MitoP/MitoB ratio at the end of ischemia (End-Isc). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. P values 
were calculated by one-way ANOVA with Dunnett’s multiple comparison test. Data are mean � SEM. 
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inhibition of SDH during normoxia (Fig. 5c). Furthermore, the serum 
creatinine concentration after 24 h reperfusion was not reduced by 
DMM (Fig. 5d). Therefore administration of DMM prior to ischemia is 
not protective against renal IR injury. 
3.7. Administration of malonate esters upon reperfusion is protective 
against renal IRI 
We next investigated whether malonate ester prodrugs could inhibit 
succinate oxidation when administered upon reperfusion. DMM (160 
mg/kg) was administered upon reperfusion of mice that had undergone 
20 min bilateral renal ischemia (Fig. 6a). DMM-infusion increased the 
malonate concentration at 10 min reperfusion (Fig. 6b). Serum creati-
nine concentration measured 24 h after reperfusion was significantly 
decreased in DMM-treated mice compared to controls (Fig. 6c) sug-
gesting DMM administered at reperfusion exerted a protective effect. It 
is probable that the protective effect of DMM was due to the inhibition of 
succinate oxidation by SDH on reperfusion as succinate was higher at the 
Fig. 4. Metabolic Changes in Mouse, Pig and Humans During Renal Ischemia. (a) A tissue wedge biopsy was taken from the kidney of anaesthetised pigs under 
conditions of normoxia and rapidly clamp frozen in LN2 using Wollenburger clamps. The renal vessels were then tied and divided, and the pig kidney was exposed to 
30 min ischemia in the abdomen of the pig maintained at the physiological of temperature 38 �C [27]. A second wedge biopsy was taken at the end of 30 min 
ischemia. (b) Human kidneys retrieved for transplantation but subsequently offered for research were reperfused with oxygenated ABO-matched blood for 1 h using 
ex vivo normothermic perfusion (EVNP). A wedge biopsy was taken from the kidney at the end of 1 h to act as a normoxic control. Human kidneys were then exposed 
to 30 min ischemia at a temperature of 36 �C. At the end of 30 min ischemia, a second wedge biopsy was taken. (c) Schematic of the EVNP circuit. (d) Succinate 
concentration (n ¼ 4), (e) ATP/ADP ratio (n ¼ 4) and (f) sum of the ATP and ADP concentration (n ¼ 4) in the kidneys of mice, pigs and humans following 30 min 
ischemia (End-Isc) relative to normoxia. (g) Absolute tissue succinate concentration in the kidneys of mice, pigs and humans during normoxia and following 30 min 
ischemia (End-Isc). Mouse kidneys were exposed to 30 min ischemia as previously described in Fig. 3b. **P < 0.01, ***P < 0.001, ****P < 0.0001. P values were 
calculated by two-way ANOVA with Sidak’s multiple comparisons test. Data are mean � SEM. 
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end of ischemia with 160 mg/kg DMM than in the absence of DMM 
(Fig. 5c) [33,34]. 
To improve the efficacy of malonate ester prodrug delivery, we also 
assessed the malonate ester prodrug diacetoxymethyl malonate (MAM), 
which is hydrolysed more rapidly than DMM thereby increasing the rate 
of malonate generation within the cell, thus allowing lower doses and/or 
better protection when given at reperfusion [23]. To test whether MAM 
was protective at lower doses than DMM, MAM was administered to 
mice at a 10x lower concentration than DMM following 20 min bilateral 
renal ischemia (Fig. 6a). 
Malonate was significantly increased in the kidneys of MAM-treated 
mice compared with controls at 10 min reperfusion (Fig. 6d). The serum 
creatinine concentration was significantly decreased in MAM treated 
mice at 24 h, suggesting MAM had a protective effect (Fig. 6e). Again, 
this was likely due to the inhibition of succinate oxidation by SDH on 
reperfusion [33,34]. Importantly, MAM also resulted in a reduction in 
serum creatinine 24 h after reperfusion (Fig. 6e), but at a 10x lower 
concentration to DMM. The fine tuning of malonate ester prodrugs is 
therefore an attractive method of improving the efficacy of these com-
pounds and reducing their unwanted off-target effects [22]. 
4. Discussion 
In this study, we show that malonate ester prodrugs may ameliorate 
IR injury in the mouse kidney if administered upon reperfusion, but not 
if given prior to ischemia. We show similar metabolic changes occur 
during ischemia in the pig and human kidney highlighting the potential 
translatability of our findings in the mouse. Furthermore, we show that 
the ‘tuned’ malonate ester prodrug, MAM, may achieve the same pro-
tective effect as the simple malonate ester prodrug, DMM, at a 10x lower 
concentration. The faster hydrolysis of MAM and lower concentration 
required for therapeutic effect is important in the specific targeting of 
succinate oxidation by SDH on reperfusion and in reducing the off-target 
effects of these compounds [22]. Given the transient increase in tissue 
malonate concentration produced by the malonate ester-prodrugs 
administered on reperfusion [33,34], it is likely that the protective ef-
fects of DMM and MAM demonstrated in this study are due to the in-
hibition of succinate oxidation by SDH on reperfusion, leading to a 
reduction in mitochondrial ROS production. MitoB was not sensitive 
enough to detect a significant increase in mitochondrial ROS production 
on reperfusion in this model and so the effect of DMM and MAM could 
not be measured directly. Nevertheless, as malonate is readily metab-
olised and excreted, its protective effect is unlikely to result from 
longer-term SDH inhibition as has been shown previously [35]. 
Administration of DMM prior to ischemia in the mouse kidney did 
not lead to a reduction in the succinate concentration, despite apparent 
inhibition of SDH. This is in contrast to previous studies in the rat brain 
[19] and mouse heart [30] although differences in compound admin-
istration, ischemia times and temperatures may also play a role. The 
metabolic conditions required for succinate accumulation via SDH 
reversal are thought to include a highly reduced NADþ/NADH pool, and 
inactivity of complexes III and IV due to the lack of oxygen [16]. It is 
unlikely these conditions occur instantaneously on the onset of ischemia 
but develop over seconds to minutes, after which SDH reversal may 
begin. In the intervening period other pathways, such as glutaminolysis 
and canonical citric acid cycle (CAC) action, may contribute to succinate 
accumulation [36]. There is uncertainty as to the contribution of ca-
nonical CAC action to overall succinate accumulation and it may be that 
the contribution of different pathways varies between organs. Metabolic 
tracing experiments may allow this question to be addressed but were 
Fig. 5. Targeting Succinate Accumulation with Dimethyl Malonate during Ischemia in the Mouse Kidney. (a) DMM was administered at the indicated doses in 
160 μL saline as an infusion (rate 16 μL/min) 10 min prior to the onset of ischemia. At the end of the infusion, immediately prior to ischemia, one kidney was 
removed and rapidly clamp frozen in LN2 using Wollenberger clamps (Pre-Isc). The second kidney was exposed to 20 min warm ischemia and then rapidly clamp 
frozen (End-Isc). Control kidneys were given a 160 μL infusion of saline only. (b & c) Tissue malonate (n ¼ 4) and succinate (n ¼ 4) concentration at the end of the 
infusion (Pre-Isc) and following 20 min ischemia (End-Isc). (d) Serum creatinine concentration (n ¼ 4) at 24 h reperfusion following infusion of saline or DMM prior 
to ischemia as described in (a) followed by 20 min bilateral renal ischemia. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. P values were calculated by two- 
way ANOVA with Sidak’s multiple comparison test (b & c) and one-way ANOVA with Dunnett’s multiple comparison test (d). Data are mean � SEM. Of note, 640 
mg/kg DMM administered prior to ischemia was toxic to the mice and the serum creatinine concentration at 24 h reperfusion could not be measured. 
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beyond the scope of our present study. 
The time of administration of DMM appears to be critical in deter-
mining its efficacy. Whilst a high malonate concentration was achieved 
in the kidneys of mice treated with DMM prior to the onset of ischemia, 
this did not lead to a reduction in renal injury compared to mice treated 
with DMM at reperfusion. As malonate ester prodrugs are not specif-
ically targeted to mitochondria and rely on passive diffusion into cells 
and hydrolysis by intracellular carboxylesterases in different cellular 
compartments [21], a number of factors may be at play that led to the 
differences in protection. 
This is the first study to demonstrate succinate accumulation occurs 
in the human and pig kidney during ischemia. EVNP of human kidneys 
retrieved for transplantation but subsequently offered for research 
provided a unique opportunity to measure the concentration of succi-
nate, ATP and ADP under conditions of normoxia. Although human 
kidneys retrieved for transplantation had previously been exposed to 
varying periods of static cold storage, succinate rapidly returns to nor-
moxic levels on reperfusion and is unaffected by ischemic pre-
conditioning [37]. Therefore this enabled us to take tissue biopsies from 
human kidneys during normoxia. This experimental platform also 
Fig. 6. Targeting Succinate Oxidation on Reperfusion with Dimethyl Malonate and Diacetoxymethyl Malonate in the Mouse Kidney. (a) Mice underwent 20 
min bilateral renal ischemia. At the end of ischemia, one kidney was removed and rapidly clamp frozen in LN2 using Wollenburger clamps (End-Isc). The second 
kidney was reperfused for 10 min and then removed and rapidly clamp frozen (Rep). An infusion of 160 μL 160 mg/kg dimethyl malonate (DMM) or 16 mg/kg 
diacetoxymethyl malonate in 1% DMSO (MAM) was given at a rate of 16 μL/min starting 5 min prior to the onset of reperfusion. Control kidneys were given an 
infusion of saline or 1% DMSO only. (b) Tissue malonate (n ¼ 4) concentration at the end of 20 min ischemia (End-Isc) and at 10 min reperfusion (Rep) in mice 
infused with 160 mg/kg DMM. (c) Serum creatinine concentration (n ¼ 6) at 24 h reperfusion following 20 min bilateral renal ischemia and infusion of saline or 160 
mg/kg of DMM as described in (a). Sham mice were infused with 160 μL saline at a rate 16 μL/min but did not undergo bilateral renal ischemia. (d) Tissue malonate 
(n ¼ 4) concentration at the end of 20 min ischemia (End-Isc) and at 10 min reperfusion (Rep) in mice infused with 16 mg/kg MAM. (e) Serum creatinine con-
centration (n ¼ 6) at 24 h reperfusion following 20 min bilateral renal ischemia and infusion of 1% DMSO or MAM as described in (a). *P < 0.05, **P < 0.01, ****P 
< 0.0001. P values were calculated by two-way ANOVA with Sidak’s multiple comparison test (b & d), one-way ANOVA with Tukey’s multiple comparison test (c) 
and an unpaired, two-tailed Student’s t-test assuming equal variance (e). Data are mean � SEM. 
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enabled human kidneys to be re-exposed to ischemia in a controlled 
manner, which is difficult to achieve in clinical settings. 
The similar levels of succinate measured in the mouse, pig and 
human under conditions of normoxia and following 30 min ischemia 
strongly suggests a conserved mechanism of succinate accumulation in 
the human kidney following EVNP and re-exposure to ischemia. As such, 
EVNP may be used to measure the metabolic changes during kidney 
ischemia and offers an attractive platform to investigate the use of 
malonate ester prodrugs within the human kidney in future translational 
studies. 
One limitation of this study is the reliance on serum creatinine as a 
sole marker of tissue injury. The mouse model of renal IR injury is 
known to be highly variable with the degree of injury affected by animal 
age, hydration status, core temperature, surgery time, surgical trauma, 
and post-operative care [38]. Numerous steps were taken to minimise 
the degree of variability as outlined in the Methods, including the use of 
a homeothermic heat mat to closely control the core temperature of the 
mouse during surgery and closure of the midline incision during 
ischemia to minimise fluid loss from evaporation. All surgeries were also 
performed by the same surgeon. However, an element of variability was 
unavoidable and may relate to changes in other factors such as surgical 
skill level over time. This may partly explain the variability in serum 
creatinine levels within this study, although all experiments consisted of 
contemporaneous control and treatment groups. Furthermore, a signif-
icant increase in tissue injury as measured by serum creatinine was only 
detected after 18 min ischemia. This is likely due to the large reserve 
capacity of the kidney with up to 50% of nephrons needing to be lost 
before a rise in serum creatinine concentration can be detected [39]. The 
findings of this study would therefore be strengthened by the analysis of 
other markers of tissue damage as well as histological analysis which 
would enable the protective effect of malonate esters on the different 
renal cell types to be probed further. In addition, experiments were 
performed using female mice only and should be confirmed in male mice 
thought to be more susceptible to IR injury [40]. 
5. Conclusion 
In conclusion, we show that succinate driven RET and mitochondrial 
ROS production act as an important therapeutic target in renal IR injury. 
The rapid oxidation of succinate by SDH may be inhibited by the 
administration of malonate ester prodrugs on reperfusion, leading to a 
reduction in mitochondrial ROS production. The alcohol groups of 
malonate ester prodrugs may be fine-tuned to increase their rate of 
hydrolysis within tissue, enabling them to act more rapidly and reduce 
the overall concentration of prodrug required to achieve therapeutic 
effect, thereby reducing unwanted off-target effects. Whilst promising 
results have been demonstrated in the mouse, translational studies are 
now required to demonstrate similar protective effects in the pig and 
human before malonate ester prodrugs may be considered for early 
clinical trials. 
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